Low-dose Rituximab and High-dose Dexamethasone as First Line Treatment for ITP

Overview

The purpose of this study is to determine the response rate and response duration with the combination of low-dose rituximab and high-dose dexamethasone in the treatment of adult immune thrombocytopenic purpura.

Full Title of Study: “Low-dose Rituximab and High-dose Dexamethasone as First Line Treatment for Adult Patients With Immune Thrombocytopenic Purpura.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: April 2010

Detailed Description

ITP is an autoimmune disorder characterized by formation of autoantibodies against platelet antigens leading platelet destruction and bleeding. Corticosteroids increase the platelet count in about 80 percent of patients.However, many patients have a relapse when the dose of corticosteroid is reduced. Debilitating side effects are common in patients who require long-term corticosteroid therapy to maintain the platelet count. Rituximab, a chimeric anti-CD20 monoclonal antibody, has been shown to be effectively raise the platelet count in some patients with ITP and there is clinical and biological evidence to suggest that, if given early, rituximab may prevent ITP relapses. Rituximab 375 mg/m2 weekly for four weeks has significant activity in patients with immune thrombocytopenia. Furthermore, using lower dose rituximab the level of B-cell depletion and the response rates appear similar to those previously observed with standard dosages in a population of ITP. The purpose of this study is to determine the response rate and response duration with the combination of low-dose rituximab (100mg IV days 1,8, 15 and 22) and high-dose dexamethasone (40mg PO days 1,2,3,4) in untreated adult patients immune thrombocytopenic purpura. A complete platelet response is defined as an increase in platelet counts to >150×109/L on two consecutive occasions. A partial response is defined as an increase in the platelet count to between 50 and 150×109/L on two consecutive occasions, 1 week apart. Duration of response is considered from the day of the initial infusion to the first time of relapse (platelet count <30×109/L)or to time of analysis.

Interventions

  • Drug: Rituximab and dexamethasone
    • Rituximab 100mg IV days 1,8,15,22. Dexamethasone 40mg PO days 1-4 (four days)

Arms, Groups and Cohorts

  • Other: Rituximab -dexamethasone
    • only one arm receive four doses weekly rituximab and four dosis daily dexamethasona

Clinical Trial Outcome Measures

Primary Measures

  • Number of patients with sustained response after 6 months
    • Time Frame: 6 months
    • Number of patients with partial and complete response after 6 months.

Secondary Measures

  • Number of patients with complete response at month 6
    • Time Frame: month 6
    • Number of patients with platelet count at least 150×109/L, 6 months after therapy
  • Bleeding
    • Time Frame: month 6
    • Number of patients with bleeding complication after therapy

Participating in This Clinical Trial

Inclusion Criteria

  • Clinically confirmed immune thrombocytopenic purpura (ITP) Platelet count less than 30,000/mm3 on two occasions. Platelets >30000/mm3 with bleeding. – Normal to increased numbers of megakaryocytes on bone marrow examination in patients ≥ 60 years – Subject is ≥ 18 years – Subject has signed and dated written informed consent. – No sepsis or fever – No active infection requiring therapy – No active chronic viral infection – HIV negative – Not pregnant or nursing – Negative pregnancy test – Fertile patients must use effective contraception Exclusion Criteria:

  • Performance status above or equal to 2. – Previous treatment with rituximab – Immunosuppressive treatment within the last month – Previous splenectomy – Presence of malignant haematological disease – Connective tissue disease – Autoimmune hemolytic anemia – Pregnancy and lactation – Not willing to participate in the study. – Expected survival of < 2 years – Known intolerance to murine antibodies.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 85 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Hospital Universitario Dr. Jose E. Gonzalez
  • Provider of Information About this Clinical Study
    • Principal Investigator: David Gomez Almaguer, Medical doctor – Hospital Universitario Dr. Jose E. Gonzalez
  • Overall Official(s)
    • David Gomez-Almaguer, MD, Principal Investigator, Hospital Universitario

References

Andersen JC. Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy. N Engl J Med. 1994 Jun 2;330(22):1560-4. doi: 10.1056/NEJM199406023302203. Erratum In: N Engl J Med 1994 Jul 28;331(4):283.

Cheng Y, Wong RS, Soo YO, Chui CH, Lau FY, Chan NP, Wong WS, Cheng G. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med. 2003 Aug 28;349(9):831-6. doi: 10.1056/NEJMoa030254.

Zaja F, Battista ML, Pirrotta MT, Palmieri S, Montagna M, Vianelli N, Marin L, Cavallin M, Bocchia M, Defina M, Ippoliti M, Ferrara F, Patriarca F, Avanzini MA, Regazzi M, Baccarani M, Isola M, Soldano F, Fanin R. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. Haematologica. 2008 Jun;93(6):930-3. doi: 10.3324/haematol.12206. Epub 2008 Apr 9.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.